Northstar Response Performed Like Tumor-Informed Assays
A new peer-reviewed study finds the methylation-based assay is effective for cancer monitoring.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Do you trust blood-based liquid biopsies as a reliable alternative to traditional tissue-based cancer testing?
The Journal of Liquid Biopsy published a study demonstrating that the Northstar Response assay performs on par with tumor-informed liquid biopsies. The analysis confirms the assay provides accurate results even in cases where traditional methods failed.
Why it matters
By removing the need for prior tumor tissue, this technology may accelerate the start of crucial molecular monitoring for cancer patients by several weeks.
Researchers evaluated 169 paired samples from 61 patients, finding a conditional R2 of 0.97 for quantitative results. The two testing approaches reached the same conclusion in 94% of sequential pairs.
The players
BillionToOne
This is the developer of the Northstar Response assay, based in Menlo Park, California.
Huntsman Cancer Institute
This research institution served as a key contributor to the peer-reviewed study.
The details
Northstar Response utilizes patented single-molecule counting technology to analyze circulating tumor DNA without requiring initial tumor tissue. In cases where results between the two assay types were discordant, the Northstar Response findings remained concordant with the established ground truth.
Timeline
October 7, 2026: The study was published in The Journal of Liquid Biopsy.
The Big Picture
This study validates the diagnostic capability of Northstar Response, reinforcing the clinical utility of methylation-based liquid biopsies as a reliable alternative to traditional tumor-informed testing. It updates the performance benchmarks previously established by the clinical adoption of methylation-based liquid biopsies.
Patients may benefit from faster initiation of molecular monitoring if their clinical team transitions to tissue-free testing methods. This shift reduces the logistical delays often associated with procuring and analyzing initial tumor biopsies.
The takeaway
Liquid biopsy technology is evolving to prioritize speed and accessibility by removing the reliance on existing tumor tissue. These findings suggest that tumor-agnostic assays are now reaching reliability levels that match established diagnostic standards.
Further reading
For more information on current diagnostic developments, visit the Cancer section.
More information
To learn more about the assay technology, visit the BillionToOne official company website.
Live Poll
Do you trust blood-based liquid biopsies as a reliable alternative to traditional tissue-based cancer testing?
